Patent: 10,751,402
✉ Email this page to a colleague
Summary for Patent: 10,751,402
| Title: | Immunogenic compositions and uses thereof |
| Abstract: | The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy. |
| Inventor(s): | Annaliesa Sybil Anderson, Leena Shriram Bagle, Amardeep Singh Bhupender Bhalla, Miguel Angel Garcia, Lei Hu, Lakshmi Khandke, Avvari Krishna Prasad, Cindy Xudong Yang |
| Assignee: | Pfizer Corp SRL |
| Application Number: | US15/800,373 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,751,402
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Glaxosmithkline Biologicals | AREXVY | respiratory syncytial virus vaccine, adjuvanted | For Injection | 125775 | May 03, 2023 | 10,751,402 | 2037-11-01 |
| Novo Nordisk Inc. | RYZODEG 70/30 | insulin degludec and insulin aspart | Injection | 203313 | September 25, 2015 | 10,751,402 | 2037-11-01 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 10,751,402
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2018087635 | ⤷ Start Trial |
| United States of America | 2024299523 | ⤷ Start Trial |
| United States of America | 2022000999 | ⤷ Start Trial |
| United States of America | 2020368340 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
